Limcato, Korea's First CAR-T Therapy, Nears Commercialization After Nine Years of Development

"Expectations for Korea to Possess Its Own CAR-T Therapy"
"LIMCARTO, Focused on Differentiation Rather Than Catch-Up"
"Competing with Solid Tumor and In Vivo CAR-T"

"The most significant aspect is that Korea will build experience and infrastructure for developing CAR-T therapies and will possess its own domestically developed treatments."

Kensoo Kim, CEO of CureCell, expressed his anticipation regarding the approval of Korea's first domestically developed CAR-T therapy, 'Limcato' (ingredient: Anvalcel), in an interview on April 3. CAR-T therapies are called "dream cancer drugs" because they use a single administration of the patient's own immune cells to target and eliminate cancer cells. However, the high cost of treatment, which can reach hundreds of millions of won, and the reliance on overseas manufacturing—which results in lengthy production times—have limited patient access. If a domestically developed CAR-T therapy is commercialized, it is expected to shorten production and logistics processes, thereby reducing waiting times for treatment and alleviating the financial burden on patients.

CureCell has devoted nine years to the development of Limcato. The Central Pharmaceutical Affairs Council (CPAC) of the Ministry of Food and Drug Safety reviewed Limcato the previous day. The CPAC is the ministry's statutory advisory body that verifies the safety and efficacy of new drugs. At this meeting, the council reportedly discussed the validity of granting conditional approval based on the results of Limcato’s Phase 2 clinical trials. Based on the CPAC's recommendations, the Ministry of Food and Drug Safety will make its final decision on whether to approve the therapy. Barring any unexpected circumstances, the industry expects approval to be granted soon.

Kensoo Kim, CEO of CureCell. CureCell

CureCell, which is leading the domestic CAR-T therapy field, aims to use its success in the Korean market as a springboard to expand overseas as quickly as possible. The company plans to secure global competitiveness through differentiated technologies such as solid tumor CAR-T and in vivo CAR-T, which induces immune cells directly within the body. CEO Kim stated, "Both solid tumor CAR-T and in vivo CAR-T are still at early clinical stages even among global companies," adding, "Since it is difficult to say who is ahead, there is ample opportunity for us."

Limcato has been designated as a target for a pilot project in which the government simultaneously conducts approval, reimbursement assessment, and drug price negotiations. As a result, the time required for the therapy to be covered by national health insurance after regulatory approval is expected to be drastically shortened compared to typical cases.

If the first domestically developed CAR-T therapy paves the way, it is expected that subsequent entrants will find it significantly easier to enter the market. This is because the pioneering case will enable the accumulation of experience in clinical trial design, manufacturing processes, and regulatory response, thereby lowering entry barriers across the industry. The Ministry of Food and Drug Safety has also prepared institutional foundations by establishing guidelines for advanced biopharmaceuticals and clarifying the approval process.

This content was produced with the assistance of AI translation services.